KRAS and lung cancer: Previous studies have shown that immune checkpoint inhibitors can improve the survival of patients with advanced non‐small cell lung cancer with KRAS mutations; however, there is a lack of comparisons between treatment regimens associated with immune checkpoint inhibitors, and our study aims to compare several treatment parties to find a more effective treatment regimen.